Scandion Oncology tackles antioestrogen resistanceScandion Oncology is currently evaluating its lead candidate SCO-101 ...
Dansk lægemiddel ser ud til at bekæmpe resistens på tværs af kræftsygdommeSABCS: Cellelinjer og farmakodynamiske studier peger på, at præparate...
+200 attendees joined our webcast todayThank you to the +200 interested attendees that joined our live webcast today...
Invitation to Scandion Oncology A/S live webcast on 20 November 2020Invitation to Scandion Oncology A/S live webcast on 20 November 2020 We ha...
CEO Bo Rode Hansen interviewed by MedWatch about rights issueCEO Bo Rode Hansen has been intervi...
CEO Bo Rode Hansen presents at InvestorUgenScandion Oncology´s President and CEO, Bo Rode Hansen will be giving a live v...
Scandion Oncology presents at Erik Penser Bank on Oct 7, 2020Scandion Oncology will present tomorrow at 13:45-14.25 at the “Temadag Cancer...
CEO Bo Rode Hansen has been interviewed about his visionsCEO Bo Rode Hansen has been interviewed by BioStock about his visions for Sca...
Interview with our new CEO, Bo Rode Hansen, and our comming CSO, Nils BrünnerOur new CEO, Bo Rode Hansen, and ou...
Interview with Scandion Oncology about new CEOScandion Oncology has just announced in a Press Release that Bo Rode Hansen h...
Live event with CEO Nils BrünnerOn ...
Strong first half of 2020 - summarized by BioStockBioStock has summarized the main achievement in Scandion oncology from the ve...
Sum up of the first clincal data with SCO-101 and FOLFIRIBioStock has made a very nice sum up of the first clincal results with SCO-10...
Press release from July 31st in SwedishWe have had many Swedish investors that asked if the English version of the p...
Live event with CEO Nils BrünnerOn August 2nd, 2020, CEO Nils Brünn...
CEO Nils Brünner is interviewed by BioStock BioStock StudioCEO Nils Brünner is interviewed by ...
Børsen article can be read here for freeWe are very happy to provide the opportunity to non-subscribers of Børsen to ...
Scandion Oncology is discussed in Nordnets InvesteringspodcastenVery nice discussion about Scandion Oncology in #Nordnet hosted by Per Hansen...
Free acess to MedWatch interview with Bo Rode Hansen about the board position in Scandion OncologyThe MedWacth interview with Bo Rode Hansen regarding his board position in Sc...
Medicon Valley Alliance interview with CEO Nils BrünnerMedicon Valley Alliance has interviewed CEO Nils Brünner about the preclinica...
CEO Nils Brünner and CEO Per Norlén (Alligator Bioscience) comments on the preclinical collaborationCEO Nils Brünner (Scandion Oncology) and CEO Per Norlén (Alligator Bioscience...
Børsen has interviewed CEO Nils Brünner about the potential of Scandion OncologyBørsen has interviewed CEO Nils Brünner about the history and potential of Sc...
Interview with CEO Nils Brünner and CEO Ole Thastrup (2cureX)BioStock has interviewed CEO Nils B...
Today Scandion Oncology presents at the AACR Virtual Annual Meeting IIAs previously announced, AACR has published a Scandion Oncology abstract for ...
Bo Rode Hansen has joined the Board of Scandion OncologyVery pleased that Bo Rode Hansen recently joined the board of Scandion Oncolo...
Live Q&A with CEO Nils Brünner and Chairman Peter HøngaardToday Scandion Oncology will present in a LIVE Q&A. From Scandion Onco...
CEO Nils Brünner interviewed by BioStock about the positive developmentCEO Nils Brünner has been interviewed about the milestones and the positive d...
MedWatch interview with CEO Nils Brünner on the collaboration between Scandion Oncology and Alligator BioscienceMedWatch has interwied CEO Nils Brü...
Exposure biomarker in clinical Phase II trial?Q: Could you explain more about the exposure biomarker mentioned in your Pres...
BioStock interview with CEO Nils Brünner on the international competition and potential for Scandion Oncology.BioStock has interviewed CEO Nils Brünner about the international competition...
AACR has published an abstract on pre-clinical effects of SCO-101 in colorectal cancerWe are happy to announce that AACR has published a Scandion Oncology abstract...
Publication of PCT application on anti microbial infectionThe Scandion Oncology PCT application "WO2020079051 - COMPOUNDS FOR TREATMENT...
BioStock interview with CSO Jan Stenvang on publication on predictive biomarkersBioStock has interviewed CSO Jan Stenvang about a new publication on irinotec...
Publication of PCT application on SRPK1The Scandion Oncology PCT application “WO2020049139 - UREA DERIVATIVES FOR US...
Patient recruitment status updatedThe recruitment for the ongoing Phase II clinical trial (ClinicalTrials.gov I...
BioStock interview with CSO Jan Stenvang on SCO-101 and docetaxelBioStock has interviewed CSO Jan Sten...
EU publication on SCANRESIST projectEU has published a "Results in Brief" article on the CORDIS website on our SC...
Interview with CEO Nils Brünner and CSO Jan Stenvang in BioStockBioStock has interviewed CEO Nils Brünner and CSO Jan Stenvang about the rece...
CEO Nils Brünner presents at the Life Science Investor Conference on March 4Økonomisk Ugebrev Life Science inviterer til årets første Investorkonfere...
CEO Presentation from Aktiespararna Investor DayCEO Nils Brünner presented at Aktispararna Investor meeting on January, 28th,...
CEO Nils Brünner will present at the Life Science Investor conference held by Økonomisk UgebrevØkonomisk Ugebrev Life Science inviterer til årets første Investorkonfere...
CEO Nils Brünner will present tomorrow at AktiespararnaCEO...
CEO Nils Brünner is interviewed by BørsenIn Børsen today CEO Nils Brünner is interviewed to the Life Science Denmark s...
BioStock article about Scandion OncologyBioStock has published an article about Scandion Oncology. The focus is on th...
Interview with CEO Nils Brünner in BioStockBioStock has intervied CEO Nils Brünner. The interview gives a short and and ...
Scandion Oncology will present at Sedermeradagen on November 18, 2019, in StockholmCEO Nils Brünner will present news from Scandion Oncology at Sedermeradagen i...
Peter Høngaard - our new Chairman of the Board - is portrayed and interview by BioStockThe full interview and portray with Peter Høngaard can be read below, or dire...
Scandion Oncology CEO Newsletter autumn 2019Nils Brünner, CEO, has summarized the current activities of Scandion Oncology...
Scandion Oncology will present on the Nordic Rise Launch Party#Scandion Oncology will join the Launch Party of Nordic Rise on Thursday 26. ...
Investor Lunch in Copenhagen on Oct 1st#Scandion Oncology looks very much forward to present at an investor lunch in...
BioStock presentation of Scandion Oncology and the ongoing Rights IssueBioStock has made a nice background about Scandion Oncology and the ongoing R...
Unit Rights for shareholdersDear Investor and current shareholder in Scandion Oncology, As a reminder ...
Rights Issue investor presentation in Copenhagen on June 25CEO Nils Brünner will present Scandion Oncology and the Rights Issue in Copen...
Scandion Oncology is now a member of Nordic RiseScandion Oncology has joined Nordic Rise, which is a focussed, ambitious and ...
Presentation and interview from BioStock LiveCEO Nils Brünner presented Scandion Oncology at the investor meeting "BioStoc...
Rights Issue investor presentations next weekCEO Nils Brünner will present Scandion Oncology and the Rights Issue at 4 inv...
CEO Nils Brünner presents today at the investor meeting "BioStock Live investerarträff"CEO Nils Brünner will present today at the investor meeting "BioStock Live in...
Watch the presentation from Småbolagsdagen 2019 in StockholmCEO Nils Brünner presented at the investor meeting Småbolagsdagen 2019 in Sto...
Scandion Oncology presents at the investor meeting Småbolagsdagen 2019 in StockholmCEO Nils Brünner will present Scandion Oncology to more than 400 investors in...
Scandion Oncology presentation from Öresundsdagen investor meetingCEO Nils Brünner presented Scandion Oncology at the Öresundsdagen investor me...
Scandion Oncology will present at Öresundsdagen in Malmö on May 20This a kind reminder that you can meet Scandion Oncology on Monday 20th in Ma...
Joint investor meeting with 2cureX on April 30On April 30...
Scandion Oncology presented in BerlingskeToday, in Berlingske there is a special issue on "Fremtidens Investeringer". ...
Scandion Oncology presentation from SedermeradagenCEO Nils Brünner presented the status and the plans for Scandion Oncology at ...
Production of SCO-101 is following the planScandion Oncology had on February 28, 2019, a face-to-face meeting with our d...
Scandion Oncology will present at Sedermeradagen in Copenhagen on March 12Sedermeradagen will take place on March 12 at the Marriott Hotel in Copenhage...
Scandion Oncology has today moved to new facilities at SymbionToday Scandion Oncology has moved to new facilities at Symbion (Fruebjergvej ...
Strategy meeting in Scandion OncologyThe BoD and management of Scandion Oncology gathered at Karlaby Kro on Dec. 1...
Presentation at the 13th Annual EORTC PatoBiology Group Meeting on September 15, 2018 in Hamburg, GermanyCSO Jan Stenvang will present data on SCO-101 and endocrine resistance in br...
Presentation at the conference “Response and Resistance in Cancer therapy” on September 10, 2018 in Kent, UKCEO Nils Brünner will present data on SCO-101 and endocrine resistance in br...
Presentation at the conference “Response and Resistance in Cancer therapy” on September 9, 2018 in Kent, UKCEO Nils Brünner will present data on SCO-101 and chemotherapy resistance at ...
Scandion has submitted a patent application regarding a novel mechanism of action for its lead compound SCO-101Scandion Oncology has discovered a novel mechanism of action for its lead com...
Scandion Oncology A/S presents at the MVA Oncology Network Pitch event at Medicon Village, Lund, Sweden, September 5th, 2018CSO Jan Stenvang will pitch the background and status of Scandion Oncology A/...
Thomas Feldthus has joined the Board of Scandion OncologyThomas Feldthus has joined the Board of Scandion Oncology. Thomas Feldthus re...
Scandion Oncology A/S signs agreement with Sedermera Fondkommission AB regarding an Initial Public Offering at Spotlight Stock Market.Scandion Oncology A/S hereby announces that an agreement has been signed w...
Scandion Oncology A/S hereby announces that an agreement has been signed w...
Scandion Oncology A/S presents at Sedermeradagen, Malmö, Sweden May 15th 2018Sedermeradagen is an investor day where Scandion Oncology A/S will present to...
Scandion Oncology A/S meets with Big Pharma at ”Focus on Cancer Collaboration” at Medicon Village, Lund, Sweden April 24thCMO Nils Brünner will present the background and status of Scandion Oncology ...
InnoBooster grant from Innovation Fund DenmarkScandion Oncology has been awarded an InnoBoster grant from Innovation Fund D...
Presentation at Danish Association for Cancer ResearchScandion Oncology will present data on SCO-101 at the annual meeting “Danish ...
Presentation at ESMO GIScandion Oncology will present data on SCO-101 at ESMO GI in Barcelona, Spain...
Saniona Spin-Out, Scandion Oncology Raises DKK 2 Million and Prepares for a Potential Public ListingSaniona, a leading biotech company in the field of ion channels, today announ...
Abstracts and poster presentations on October 28, 2017Abstracts and poster presentations on October 28, 2017, at the AACR-NCI-EORTC...
Poster presentation on November 1, 2017Poster presentation on November 1, 2017, at the Biomarker AGORA 2017, Copenha...